Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor OPtimization and Selectivity trial

François Guilhot, Timothy P. Hughes, Jorge Cortes, Brian Druker, Michele Baccarani, Insa Gathmann, Michael Hayes, Camille Granvil, Yanfeng Wang

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Background This study evaluates the correlation between imatinib trough plasma concentrations (C min) and clinical response and safety in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase in the Tyrosine Kinase Inhibitor OPtimization and Selectivity (TOPS) trial. Design and Methods Patients were randomized 1:2 to 400 mg/day or 800 mg/day imatinib. Imatinib C min levels were collected at pre-dose before treatment, and at the end of months 1 (day 29), 6, 9, and 12. Results Imatinib C min were stable over time in the 400 mg/day dose arm, but showed a slight decrease in the 800 mg/day arm due to dose adjustments between months 1-6. The overall median imatinib C min levels were 1040, 1200, 1935, and 2690 ng/mL for the actual 300, 400, 600, and 800 mg/day doses, respectively. The rates of major molecular response (MMR) at 3, 6, 9, and 12 months, and complete cytogenetic response (CCyR) at 6 and 12 months were significantly lower among patients with the lowest imatinib C min levels at Day 29 (th percentile). There was an apparent association between high imatinib C min and the occurrence of grade 3/4 neutropenia and all-grade rash, diarrhea, arthralgia/myalgia, and all-cause edema. Conclusions Imatinib C min levels were relatively stable over time and proportional to the dose administered. Patients with an imatinib C min above 1165 ng/mL on Day 29 achieved MMR faster and had higher MMR and CCyR rates at 12 months. There appeared to be an association between imatinib C min and the frequency of some adverse events.

Original languageEnglish (US)
Pages (from-to)731-738
Number of pages8
JournalHaematologica
Volume97
Issue number5
DOIs
StatePublished - May 1 2012

Fingerprint

Protein-Tyrosine Kinases
Cytogenetics
Imatinib Mesylate
Leukemia, Myeloid, Chronic Phase
Social Adjustment
Philadelphia Chromosome
Myalgia
Arthralgia
Patient Safety
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Exanthema
Neutropenia
Diarrhea
Edema

Keywords

  • Chronic myeloid leukemia
  • Imatinib
  • Pharmacokinetics
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Hematology

Cite this

Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor OPtimization and Selectivity trial. / Guilhot, François; Hughes, Timothy P.; Cortes, Jorge; Druker, Brian; Baccarani, Michele; Gathmann, Insa; Hayes, Michael; Granvil, Camille; Wang, Yanfeng.

In: Haematologica, Vol. 97, No. 5, 01.05.2012, p. 731-738.

Research output: Contribution to journalArticle

Guilhot, François ; Hughes, Timothy P. ; Cortes, Jorge ; Druker, Brian ; Baccarani, Michele ; Gathmann, Insa ; Hayes, Michael ; Granvil, Camille ; Wang, Yanfeng. / Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor OPtimization and Selectivity trial. In: Haematologica. 2012 ; Vol. 97, No. 5. pp. 731-738.
@article{5c7622fbcfb74334a172765349a1f102,
title = "Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor OPtimization and Selectivity trial",
abstract = "Background This study evaluates the correlation between imatinib trough plasma concentrations (C min) and clinical response and safety in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase in the Tyrosine Kinase Inhibitor OPtimization and Selectivity (TOPS) trial. Design and Methods Patients were randomized 1:2 to 400 mg/day or 800 mg/day imatinib. Imatinib C min levels were collected at pre-dose before treatment, and at the end of months 1 (day 29), 6, 9, and 12. Results Imatinib C min were stable over time in the 400 mg/day dose arm, but showed a slight decrease in the 800 mg/day arm due to dose adjustments between months 1-6. The overall median imatinib C min levels were 1040, 1200, 1935, and 2690 ng/mL for the actual 300, 400, 600, and 800 mg/day doses, respectively. The rates of major molecular response (MMR) at 3, 6, 9, and 12 months, and complete cytogenetic response (CCyR) at 6 and 12 months were significantly lower among patients with the lowest imatinib C min levels at Day 29 (th percentile). There was an apparent association between high imatinib C min and the occurrence of grade 3/4 neutropenia and all-grade rash, diarrhea, arthralgia/myalgia, and all-cause edema. Conclusions Imatinib C min levels were relatively stable over time and proportional to the dose administered. Patients with an imatinib C min above 1165 ng/mL on Day 29 achieved MMR faster and had higher MMR and CCyR rates at 12 months. There appeared to be an association between imatinib C min and the frequency of some adverse events.",
keywords = "Chronic myeloid leukemia, Imatinib, Pharmacokinetics, Tyrosine kinase inhibitor",
author = "Fran{\cc}ois Guilhot and Hughes, {Timothy P.} and Jorge Cortes and Brian Druker and Michele Baccarani and Insa Gathmann and Michael Hayes and Camille Granvil and Yanfeng Wang",
year = "2012",
month = "5",
day = "1",
doi = "10.3324/haematol.2011.045666",
language = "English (US)",
volume = "97",
pages = "731--738",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "5",

}

TY - JOUR

T1 - Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor OPtimization and Selectivity trial

AU - Guilhot, François

AU - Hughes, Timothy P.

AU - Cortes, Jorge

AU - Druker, Brian

AU - Baccarani, Michele

AU - Gathmann, Insa

AU - Hayes, Michael

AU - Granvil, Camille

AU - Wang, Yanfeng

PY - 2012/5/1

Y1 - 2012/5/1

N2 - Background This study evaluates the correlation between imatinib trough plasma concentrations (C min) and clinical response and safety in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase in the Tyrosine Kinase Inhibitor OPtimization and Selectivity (TOPS) trial. Design and Methods Patients were randomized 1:2 to 400 mg/day or 800 mg/day imatinib. Imatinib C min levels were collected at pre-dose before treatment, and at the end of months 1 (day 29), 6, 9, and 12. Results Imatinib C min were stable over time in the 400 mg/day dose arm, but showed a slight decrease in the 800 mg/day arm due to dose adjustments between months 1-6. The overall median imatinib C min levels were 1040, 1200, 1935, and 2690 ng/mL for the actual 300, 400, 600, and 800 mg/day doses, respectively. The rates of major molecular response (MMR) at 3, 6, 9, and 12 months, and complete cytogenetic response (CCyR) at 6 and 12 months were significantly lower among patients with the lowest imatinib C min levels at Day 29 (th percentile). There was an apparent association between high imatinib C min and the occurrence of grade 3/4 neutropenia and all-grade rash, diarrhea, arthralgia/myalgia, and all-cause edema. Conclusions Imatinib C min levels were relatively stable over time and proportional to the dose administered. Patients with an imatinib C min above 1165 ng/mL on Day 29 achieved MMR faster and had higher MMR and CCyR rates at 12 months. There appeared to be an association between imatinib C min and the frequency of some adverse events.

AB - Background This study evaluates the correlation between imatinib trough plasma concentrations (C min) and clinical response and safety in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase in the Tyrosine Kinase Inhibitor OPtimization and Selectivity (TOPS) trial. Design and Methods Patients were randomized 1:2 to 400 mg/day or 800 mg/day imatinib. Imatinib C min levels were collected at pre-dose before treatment, and at the end of months 1 (day 29), 6, 9, and 12. Results Imatinib C min were stable over time in the 400 mg/day dose arm, but showed a slight decrease in the 800 mg/day arm due to dose adjustments between months 1-6. The overall median imatinib C min levels were 1040, 1200, 1935, and 2690 ng/mL for the actual 300, 400, 600, and 800 mg/day doses, respectively. The rates of major molecular response (MMR) at 3, 6, 9, and 12 months, and complete cytogenetic response (CCyR) at 6 and 12 months were significantly lower among patients with the lowest imatinib C min levels at Day 29 (th percentile). There was an apparent association between high imatinib C min and the occurrence of grade 3/4 neutropenia and all-grade rash, diarrhea, arthralgia/myalgia, and all-cause edema. Conclusions Imatinib C min levels were relatively stable over time and proportional to the dose administered. Patients with an imatinib C min above 1165 ng/mL on Day 29 achieved MMR faster and had higher MMR and CCyR rates at 12 months. There appeared to be an association between imatinib C min and the frequency of some adverse events.

KW - Chronic myeloid leukemia

KW - Imatinib

KW - Pharmacokinetics

KW - Tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84860549849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860549849&partnerID=8YFLogxK

U2 - 10.3324/haematol.2011.045666

DO - 10.3324/haematol.2011.045666

M3 - Article

C2 - 22315495

AN - SCOPUS:84860549849

VL - 97

SP - 731

EP - 738

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 5

ER -